Rare Genetic Mutation Identified as Direct Cause of Fatty Liver Disease
A groundbreaking discovery by researchers at Mayo Clinic’s Center for Individualized Medicine has pinpointed a rare genetic variant as a direct cause of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD). This finding challenges the long-held belief that MASLD primarily develops from a combination of genetic predisposition and lifestyle factors, revealing that, in some cases, a single inherited mutation can be the primary driver of the disease. The research, published in the journal Hepatology, offers new avenues for understanding and potentially treating this increasingly prevalent condition.
Affecting roughly one-third of adults worldwide, MASLD is characterized by an accumulation of fat in the liver. Its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), is projected to become the leading cause of cirrhosis and liver transplantation in the coming years, making this discovery particularly timely. MASLD can progress from simple fat accumulation to inflammation, fibrosis (scarring), and cirrhosis, potentially leading to liver failure or liver cancer.
“This discovery opens a window into how rare inherited genetic variants can drive common diseases,” explains Dr. Filippo Pinto e Vairo, medical director of the Program for Rare and Undiagnosed Diseases at Mayo Clinic’s Center for Individualized Medicine, and lead author of the study. “It provides new insights into this disease pathogenesis and potential therapeutic targets for future research.” The identification of this specific genetic link represents a significant step forward in personalized medicine approaches to liver health.
Unraveling the Genetic Clue: The MET Gene
The research team traced the causative variant to the MET gene, a crucial component in liver repair and fat metabolism. When the MET gene doesn’t function correctly, fat accumulates within liver cells, initiating a cascade of inflammation and potential damage. This buildup, over time, can lead to the development of fibrosis, the scarring that stiffens the liver, and cirrhosis. The team’s investigation began with a family – a woman and her father – both diagnosed with MASH, despite lacking common risk factors like diabetes or high cholesterol.
Recognizing that conventional explanations didn’t fully account for their condition, researchers embarked on an extensive genetic analysis, scrutinizing DNA across more than 20,000 genes. This meticulous search revealed a subtle, yet potentially significant, alteration within the MET gene. Collaboration with scientists from the Medical College of Wisconsin’s John & Linda Mellowes Center for Genomic Sciences and Precision Medicine, led by Dr. Raul Urrutia, confirmed that this mutation disrupted a critical biological process. Specifically, a single “swapped letter” within the DNA sequence interfered with the liver’s ability to process fat effectively. This particular genetic variant had not been previously documented in scientific literature or public genetic databases.
Dr. Urrutia emphasized the broader implications of the finding, stating, “This study demonstrates that rare diseases are not rare but often hidden in the large pool of complex disorders, underscoring the immense power of individualized medicine in identifying them, and enabling the design of advanced diagnostics and targeted therapies.”
Tapestry Study Confirms Genetic Link in Wider Population
To determine if the identified MET gene variant was isolated to this single family, researchers turned to data from Mayo Clinic’s Tapestry study, a large-scale exome sequencing initiative. The Tapestry project, which has analyzed the germline DNA of over 100,000 participants across the United States, aims to identify genetic factors influencing disease development. Mayo Clinic Health System details the importance of understanding steatotic liver disease.
Analysis of nearly 4,000 adults within the Tapestry study who had been diagnosed with MASLD revealed that approximately 1% carried rare variants in the MET gene. Importantly, nearly 18% of these variants occurred in the same key region identified in the original family, providing strong evidence supporting the gene’s role in the development of the disease. Dr. Konstantinos Lazaridis, Carlson and Nelson Endowed Executive Director for the Center for Individualized Medicine, estimates that this finding could potentially impact “hundreds of thousands, if not millions, of people worldwide” who are affected by or at risk for MASLD.
Dr. Lazaridis further highlighted the value of the Tapestry study in uncovering hidden genetic factors. “Once a pathogenic variant is discovered, interrogating our Tapestry data repository is giving us a clearer lens into the hidden layers of disease, and this discovery is one of the first to demonstrate its scientific significance,” he stated. “This finding highlights the profound value of studying familial diseases and the merit of large-scale genomic datasets, which can reveal rare genetic variations with broader implications for population health.”
The Growing Role of Precision Genomics in Liver Disease Diagnosis
This research underscores the increasing importance of genomic medicine in clinical practice. Since its launch in 2019, Mayo Clinic’s Program for Rare and Undiagnosed Diseases has provided comprehensive genomic testing to over 3,200 patients, working with nearly 300 clinicians across 14 divisions to deliver precision diagnostics for challenging cases, including rare liver diseases. The program’s success demonstrates the power of advanced genetic technologies in uncovering the underlying causes of complex illnesses.
Researchers are now focusing on future studies to explore how this discovery regarding MASLD can inform the development of targeted treatments and improve diagnostic strategies. Understanding the specific genetic mechanisms driving the disease will be crucial in designing therapies that address the root cause, rather than simply managing the symptoms. The identification of the MET gene variant represents a significant step towards a more personalized and effective approach to treating MASLD and preventing its progression to more severe liver conditions.
Key Takeaways
- A rare genetic mutation in the MET gene has been identified as a direct cause of MASLD in some individuals.
- The discovery challenges the traditional understanding of MASLD as solely a lifestyle-related disease.
- The Mayo Clinic’s Tapestry study played a crucial role in confirming the genetic link in a larger population.
- This finding opens new avenues for developing targeted therapies and improving diagnosis of MASLD.
The ongoing research into MASLD and the application of genomic medicine promise to revolutionize the way we understand and treat this increasingly common liver disease. Further studies are planned to investigate the prevalence of this MET gene variant in diverse populations and to explore potential therapeutic interventions. The next steps will involve detailed functional studies to fully elucidate how the mutation disrupts liver function and contributes to disease development.
What are your thoughts on this new discovery? Share your comments below, and please share this article with anyone who might find this information valuable.